Gedeon Richter Plc - Company Profile
Powered by 
All the sales intelligence you need on Gedeon Richter Plc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Gedeon Richter Plc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Gedeon Richter Plc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Gedeon Richter Plc (Richter) is a pharmaceutical company that develops, manufactures and markets an array of drugs, including original, generic, and licensed products and over the counter (OTC) medicines. The company’s product portfolio consists of medicines to treat gastrointestinal diseases, gynaecological diseases cardiovascular diseases and central nervous system disorders. Richter’s research activities focus exclusively on the development of original small molecules, recombinant biotechnology, and generic product development. It operates a sales network in Hungary, Central Eastern Europe, and the Commonwealth of Independent States (CIS) countries. The company has a research and development unit in Central Eastern Europe. Richter is headquartered in Budapest, Hungary.
Headquarters
Hungary
Address
Gyomroi Ut 19-21., Budapest, 1103
Website
www.gedeonrichter.com/hu-hu
Telephone
36 1 4314000
No of Employees
11,955
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
RICHTER (BDP)
Revenue (2024)
$2.6B
8.3%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-2.9%
(2024 vs 2023)
Market Cap*
$6.9B
Net Profit Margin (2024)
XYZ
-10.4%
(2024 vs 2023)
* As of and is in US$
Gedeon Richter Plc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Gynecological | Contract Development and Manufacturing (CDMO): | Aflamin |
| Contraceptive and Emergency Contraceptive Pills | Microbial and Mammalian Cell Line Development | Vraylar |
| Hormone Replacement Therapy (HRT) Treatments | Mammalian Cell Culture Fermentation | Evra |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In June, the company entered into an agreement with Hetero Labs Ltd to jointly develop, register and commercialize semaglutide injection (generic Ozempic ). |
| 2026 | Contracts/Agreements | In May, the company expanding an agreement with Acrux Limited for Lenzetto, a transdermal estradiol spray for menopausal hormone therapy. |
| 2026 | Asset Purchase | In March, the company acquired Celmatix Inc.'s women’s health discovery portfolio. |
Competitor Comparison
| Key Parameters | Gedeon Richter Plc | EGIS Pharmaceuticals Plc | Theramex HQ UK Ltd | TherapeuticsMD Inc | Besins Healthcare SA |
|---|---|---|---|---|---|
| Headquarters | Hungary | Hungary | United Kingdom | United States of America | Monaco |
| City | Budapest | Budapest | London | Boca Raton | Monaco |
| State/Province | - | Central Transdanubia | England | Florida | - |
| No. of Employees | 11,955 | 4,600 | 141 | 1 | - |
| Entity Type | Public | Private | Private | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Dr. Szilveszter E. Vizi | Chairman | Executive Board | 2024 | - |
| Gabor Orban | Chief Executive Officer; Director | Executive Board | 2017 | - |
| Laszlo Andras Kovacs | Chief Financial Officer - Deputy; Director | Executive Board | 2025 | - |
| Andras Laszlo Kovacs | Chief Executive Officer - Deputy; Chief Financial Officer | Senior Management | 2019 | - |
| Attila Szenasi | Director - Production and Logistics | Senior Management | 2019 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer